Skip to main content

Table 6 Publications on late toxicity of radiotherapy of the prostate bed with or without pelvic irradiation

From: Helical intensity-modulated Radiotherapy of the Pelvic Lymph Nodes with Integrated Boost to the Prostate Bed - Initial Results of the PLATIN 3 Trial

  Median follow-up Late grade 1 Late grade 2 Late grade 3 Late grade 4
    GI GU GI GU GI GU GI GU
Bolla et al. [1] 3D-CRT prostate bed 66.0 Gy 60 months - - - - 4.2% 0% 0%
Bolla et al. [12] 3D-CRT prostate bed 66.0 Gy 127 months - - - - 5.3% 0% 0%
Wiegel et al. [3] 3D-CRT prostate bed 66.60 Gy 54 months - - 1.4% 2.0% - 0.5% 0% 0%
Bellavita et al. [13] 3D-CRT prostate bed 66.6 Gy 56 months 7.1% (G1/2) 9.9% (G1/2) - - 0.5% 5.5% 0% 0%
Ost et al. [18] IMRT/3D-CRT prostate bed 69.1 Gy 60 months 28% 34% 5% 17% < 1% 10% 0% 0%
Current trial IMRT WPRT 51 Gy + boost prostate bed 68 Gy 24 months 7.5% 22.5% 10.0% 5.0% 5.0% 0% 0% 0%
Deville et al.[15] IMRT WPRT 45 Gy Gy + boost prostate bed 70.2 Gy 26 months 11% 50% 3% 17% 0% 11% 0% 0%
Aizer et al.[16] 3D-CRT WPRT 45 Gy + IMRT boost prostate 75.6 Gy 30 months 2.9% 1.5% 4.4% 1.5% 1.5% 0% 0% 0%
Roach et al.[4] 3D-CRT WPRT 45 Gy + boost prostate 70.2 Gy - - - - - 4.3% (G3/4) 3.0% (G3/4) - -
  1. Published data on late toxicity of adjuvant 3D conformal radiotherapy (3D-CRT) of the prostate bed (regular print), adjuvant intensity-modulated radiotherapy (IMRT) of the whole pelvis (WPRT) with a boost to the prostate bed (bold print) and definitive or adjuvant 3D-CRT WPRT with a boost to the prostate or prostate bed (italic print). (GI = gastrointestinal, GU = genitourinary).